Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

StatusNot Yet Recruiting
PhasePhase 1
SponsorAmgen
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Amgen
169 trials monitored
See 11 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
The primary objective of this trial is to evaluate the pharmacokinetics (PK) of two maridebart cafraglutide drug products in participants living with overweight or obesity.
Trial Details
NCT Number NCT07832799
Lead Sponsor Amgen
Conditions
(from sponsor)		 Overweight, Obesity
Related terms Obesity, Overweight
Enrollment 340 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov